Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00286429
Recruitment Status : Completed
First Posted : February 3, 2006
Results First Posted : August 12, 2011
Last Update Posted : February 3, 2012
Sponsor:
Information provided by (Responsible Party):
Takeda

Tracking Information
First Submitted Date  ICMJE February 1, 2006
First Posted Date  ICMJE February 3, 2006
Results First Submitted Date  ICMJE June 8, 2011
Results First Posted Date  ICMJE August 12, 2011
Last Update Posted Date February 3, 2012
Study Start Date  ICMJE February 2006
Actual Primary Completion Date May 2007   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 19, 2011)
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26. [ Time Frame: Baseline and Week 26. ]
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 26 or final visit and glycosylated hemoglobin collected at baseline.
Original Primary Outcome Measures  ICMJE
 (submitted: February 1, 2006)
Change in HbA1c at end of study
Change History Complete list of historical versions of study NCT00286429 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: July 19, 2011)
  • Change From Baseline in Glycosylated Hemoglobin (Week 4). [ Time Frame: Baseline and Week 4. ]
    The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and Glycosylated Hemoglobin collected at baseline.
  • Change From Baseline in Glycosylated Hemoglobin (Week 8). [ Time Frame: Baseline and Week 8. ]
    The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and Glycosylated Hemoglobin collected at baseline.
  • Change From Baseline in Glycosylated Hemoglobin (Week 12). [ Time Frame: Baseline and Week 12. ]
    The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and Glycosylated Hemoglobin collected at baseline.
  • Change From Baseline in Glycosylated Hemoglobin (Week 16). [ Time Frame: Baseline and Week 16. ]
    The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and Glycosylated Hemoglobin collected at baseline.
  • Change From Baseline in Glycosylated Hemoglobin (Week 20). [ Time Frame: Baseline and Week 20. ]
    The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and Glycosylated Hemoglobin collected at baseline.
  • Change From Baseline in Fasting Plasma Glucose (Week 1). [ Time Frame: Baseline and Week 1. ]
    The change between the value of fasting plasma glucose collected at final visit or week 1 and fasting plasma glucose collected at baseline.
  • Change From Baseline in Fasting Plasma Glucose (Week 2). [ Time Frame: Baseline and Week 2. ]
    The change between the value of fasting plasma glucose collected at week 2 and fasting plasma glucose collected at baseline.
  • Change From Baseline in Fasting Plasma Glucose (Week 4). [ Time Frame: Baseline and Week 4. ]
    The change between the value of fasting plasma glucose collected at week 4 and fasting plasma glucose collected at baseline.
  • Change From Baseline in Fasting Plasma Glucose (Week 8). [ Time Frame: Baseline and Week 8. ]
    The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline.
  • Change From Baseline in Fasting Plasma Glucose (Week 12). [ Time Frame: Baseline and Week 12. ]
    The change between the value of fasting plasma glucose collected at week 12 and fasting plasma glucose collected at baseline.
  • Change From Baseline in Fasting Plasma Glucose (Week 16). [ Time Frame: Baseline and Week 16. ]
    The change between the value of fasting plasma glucose collected at week 16 and fasting plasma glucose collected at baseline.
  • Change From Baseline in Fasting Plasma Glucose (Week 20). [ Time Frame: Baseline and Week 20. ]
    The change between the value of fasting plasma glucose collected at week 20 and fasting plasma glucose collected at baseline.
  • Change From Baseline in Fasting Plasma Glucose (Week 26). [ Time Frame: Baseline and Week 26. ]
    The change between the value of fasting plasma glucose collected at week 26 or final visit and fasting plasma glucose collected at baseline.
  • Number of Participants With Marked Hyperglycemia (Fasting Plasma Glucose ≥ 200 mg Per dL). [ Time Frame: 26 Weeks. ]
    The number of participants with a fasting plasma glucose value greater than or equal to 200 mg per dL during the 26 week study.
  • Number of Participants Requiring Rescue. [ Time Frame: 26 Weeks. ]
    The number of participants requiring rescue for failing to achieve pre-specified glycemic targets during the 26 week study.
  • Change From Baseline in C-peptide (Week 4). [ Time Frame: Baseline and Week 4. ]
    The change between the value of C-peptide collected at week 4 and C-peptide collected at baseline.
  • Change From Baseline in C-peptide (Week 8). [ Time Frame: Baseline and Week 8. ]
    The change between the value of C-peptide collected at week 8 and C-peptide collected at baseline.
  • Change From Baseline in C-peptide (Week 12). [ Time Frame: Baseline and Week 12. ]
    The change between the value of C-peptide collected at week 12 and C-peptide collected at baseline.
  • Change From Baseline in C-peptide (Week 16). [ Time Frame: Baseline and Week 16. ]
    The change between the value of C-peptide collected at week 16 and C-peptide collected at baseline.
  • Change From Baseline in C-peptide (Week 20). [ Time Frame: Baseline and Week 20. ]
    The change between the value of C-peptide collected at week 20 and C-peptide collected at baseline.
  • Change From Baseline in C-peptide (Week 26). [ Time Frame: Baseline and Week 26. ]
    The change between the value of C-peptide collected at week 26 or final visit and C-peptide collected at baseline.
  • Number of Participants With Glycosylated Hemoglobin ≤ 6.5%. [ Time Frame: Baseline and Week 26. ]
    The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 6.5% during the 26 week study.
  • Number of Participants With Glycosylated Hemoglobin ≤ 7.0%. [ Time Frame: Baseline and Week 26. ]
    The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 7.0% during the 26 week study.
  • Number of Participants With Glycosylated Hemoglobin ≤ 7.5%. [ Time Frame: Baseline and Week 26. ]
    The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 7.5% during the 26 week study.
  • Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 0.5%. [ Time Frame: Baseline and Week 26. ]
    The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 0.5% during the 26 week study.
  • Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.0%. [ Time Frame: Baseline and Week 26. ]
    The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 1.0% during the 26 week study.
  • Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.5%. [ Time Frame: Baseline and Week 26. ]
    The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 1.5% during the 26 week study.
  • Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 2.0%. [ Time Frame: Baseline and Week 26. ]
    The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 2.0% during the 26 week study.
  • Change From Baseline in Body Weight (Week 8). [ Time Frame: Baseline and Week 8. ]
    The change between Body Weight measured at week 8 and Body Weight measured at baseline.
  • Change From Baseline in Body Weight (Week 12). [ Time Frame: Baseline and Week 12. ]
    The change between Body Weight measured at week 12 and Body Weight measured at baseline.
  • Change From Baseline in Body Weight (Week 20). [ Time Frame: Baseline and Week 20. ]
    The change between Body Weight measured at week 20 and Body Weight measured at baseline.
  • Change From Baseline in Body Weight (Week 26). [ Time Frame: Baseline and Week 26. ]
    The change between Body Weight measured at week 26 or final visit and Body Weight measured at baseline.
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.
Official Title  ICMJE A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Insulin in Subjects With Type 2 Diabetes
Brief Summary The purpose of this study is to determine the efficacy and safety of alogliptin, once daily (QD), taken in combination with insulin for the treatment of Type 2 Diabetes.
Detailed Description

There are approximately 19 million people in the United States who have been diagnosed with diabetes mellitus, of which 90% to 95% are type 2. The prevalence of type 2 diabetes varies among racial and ethnic populations and has been shown to correlate with age, obesity, family history, history of gestational diabetes, and physical inactivity. Over the next decade, a marked increase in the number of adults with diabetes mellitus is expected.

Takeda is developing alogliptin (SYR-322) for patients with type 2 diabetes mellitus. Alogliptin is an inhibitor of the dipeptidyl peptidase IV enzyme. Dipeptidyl peptidase IV is thought to be primarily responsible for the degradation of 2 peptide hormones released in response to nutrient ingestion. It is expected that inhibition of dipeptidyl peptidase IV will improve glycemic (glucose) control in patients with type 2 diabetes.

The aim of the current study is to evaluate the efficacy of alogliptin in combination with insulin in subjects who are inadequately controlled on insulin alone (with or without metformin). Individuals who participate in this study will be required to commit to a screening visit and up to 14 additional visits at the study center. Study participation is anticipated to be about 34 weeks (or 8.5 months).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Diabetes Mellitus
Intervention  ICMJE
  • Drug: Alogliptin and insulin
    Alogliptin 12.5 mg, tablets, orally, once daily and insulin for up to 26 weeks.
    Other Names:
    • alogliptin
    • SYR110322
  • Drug: Alogliptin and insulin
    Alogliptin 25 mg, tablets, orally, once daily and insulin for up to 26 weeks.
    Other Names:
    • alogliptin
    • SYR110322
  • Drug: Insulin
    Alogliptin placebo-matching tablets, orally, once daily and insulin for up to 26 weeks.
Study Arms  ICMJE
  • Placebo Comparator: Insulin
    Intervention: Drug: Insulin
  • Experimental: Alogliptin 12.5 mg QD
    Intervention: Drug: Alogliptin and insulin
  • Experimental: Alogliptin 25 mg QD
    Intervention: Drug: Alogliptin and insulin
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 19, 2011)
390
Original Enrollment  ICMJE
 (submitted: February 1, 2006)
300
Actual Study Completion Date  ICMJE May 2007
Actual Primary Completion Date May 2007   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria

  • Diagnosis of type 2 diabetes mellitus and currently treated with insulin alone (with or without metformin), and is inadequately controlled. Metformin dose must be stable for at least 8 weeks prior to Randomization.
  • No treatment with antidiabetic agents other than insulin and metformin within the 8 weeks prior to Randomization.
  • Body mass index greater than or equal to 23 kg/m2 and less than or equal to 45 kg/m2
  • Fasting C-peptide concentration greater than or equal to 0.8 ng per mL. (If this screening criterion is not met, the subject still qualifies if C-peptide greater than or equal to 1.5 ng per mL after a challenge test).
  • Glycosylated hemoglobin concentration greater than or equal to 8.0% at Screening.
  • Using a stable dose of insulin of at least 15 units but not more than 100 units per day for at least 8 weeks prior to Randomization. A dose of insulin that varies by up to 15% of the mean will be considered as stable.
  • If regular use of other, non-excluded medications, must be on a stable dose for at least the 4 weeks prior to Screening. However, as needed use of prescription or over-the-counter medications is allowed at the discretion of the investigator.
  • Systolic blood pressure less than or equal to180 mm Hg and diastolic pressure less than or equal to 110 mm Hg
  • Hemoglobin greater than or equal to 12 g per dL for males and greater than or equal to10 g per dL for females.
  • Alanine aminotransferase less than or equal to 3 times the upper limit of normal.
  • Serum creatinine less than or equal to 2.0 mg per dL.
  • Thyroid-stimulating hormone level less than or equal to the upper limit of the normal range and the subject is clinically euthyroid.
  • Neither pregnant (confirmed by laboratory testing in females of childbearing potential) nor lactating.
  • Female subjects of childbearing potential must be practicing adequate contraception. Adequate contraception must be practiced for the duration of participation in the study.
  • Able and willing to monitor own blood glucose concentrations with a home glucose monitor
  • No major illness or debility that in the investigator's opinion prohibits the individual from completing the study
  • Able and willing to provide written informed consent

Exclusion Criteria

  • Urine albumin to creatinine ratio of greater than 1000 μg per mg at Screening. If elevated, the subject may be rescreened within 1 week.
  • History of cancer, other than squamous cell or basal cell carcinoma of the skin, that has not been in full remission for at least 5 years prior to Screening. (History of treated cervical intraepithelial neoplasia I or cervical intraepithelial neoplasia II is allowed.).
  • History of laser treatment for proliferative diabetic retinopathy within the 6 months prior to Screening.
  • History of treated diabetic gastric paresis.
  • New York Heart Association Class III or IV heart failure regardless of therapy. Currently treated subjects who are stable at Class I or II are candidates for the study.
  • History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within the 6 months prior to Screening.
  • History of any hemoglobinopathy that may affect determination of glycosylated hemoglobin.
  • History of infection with hepatitis B, hepatitis C, or human immunodeficiency virus.
  • History of a psychiatric disorder that will affect ability to participate in the study.
  • History of angioedema in association with use of angiotensin-converting enzyme inhibitors or angiotensin-II receptor inhibitors.
  • History of alcohol or substance abuse within the 2 years prior to Screening.
  • Receipt of any investigational drug within the 30 days prior to Screening or a history of receipt of an investigational antidiabetic drug within the 3 months prior to Screening.
  • Prior treatment in an investigational study of alogliptin.
  • Excluded Medications:

    • Treatment with antidiabetic agents other than insulin and metformin is not allowed within the 8 weeks prior to Randomization and through the completion of the end-of treatment or early termination procedures. (Exception: if has received other antidiabetic therapy for less than 7 days within the 3 months prior to Screening.)
    • Treatment with weight-loss drugs, any investigational antidiabetics, or oral or systemically injected glucocorticoids is not allowed from 3 months prior to randomization through the completion of the end-of-treatment or early termination procedures. Inhaled corticosteroids are allowed.
    • Must not take any medications, including over-the-counter products, without first consulting with the investigator.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Australia,   Brazil,   Chile,   Czech Republic,   Germany,   Guatemala,   Hungary,   India,   Mexico,   Netherlands,   New Zealand,   Peru,   Poland,   South Africa,   United States
Removed Location Countries Spain
 
Administrative Information
NCT Number  ICMJE NCT00286429
Other Study ID Numbers  ICMJE SYR-322-INS-011
2005-004671-38 ( EudraCT Number )
U1111-1113-8369 ( Registry Identifier: WHO )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Takeda
Study Sponsor  ICMJE Takeda
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: VP Biological Sciences Takeda
PRS Account Takeda
Verification Date February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP